Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,081 to 1,100 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative transcriptome and chromatin landscape analysis reveals distinct epigenetic regulations in human memory B cells. | Nat Commun | 2020 | 33116135 | PubTator, text mining | PubMed |
| [Abnormal expression of WWP1 in chronic lymphocytic leukemia and its clinical significance]. | Zhonghua Xue Ye Xue Za Zhi | 2020 | 33113605 | PubTator, text mining | PubMed |
| DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia. | Int J Mol Sci | 2020 | 33081245 | PubTator, text mining | PubMed |
| [Fluorescence in Situ Hybridization for Detecting Molecular Cytogenetic Abnormalities of Chronic Lymphocytic Leukemia]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2020 | 33067940 | PubTator, text mining | PubMed |
| Focal adhesion ribonucleoprotein complex proteins are major humoral cancer antigens and targets in autoimmune diseases. | Commun Biol | 2020 | 33067514 | PubTator, text mining | PubMed |
| Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). | Hemasphere | 2020 | 33062946 | PubTator, text mining | PubMed |
| Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia. | Onco Targets Ther | 2020 | 33061448 | PubTator, text mining | PubMed |
| Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. | Haematologica | 2020 | 33054124 | PubTator, text mining | PubMed |
| Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. | Haematologica | 2020 | 33054096 | PubTator, text mining | PubMed |
| Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. | Cancers (Basel) | 2020 | 33050534 | PubTator, text mining | PubMed |
| Autoreactivity of Broadly Neutralizing Influenza Human Antibodies to Human Tissues and Human Proteins. | Viruses | 2020 | 33049994 | PubTator, text mining | PubMed |
| SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. | Nature | 2020 | 33045718 | PubTator, text mining | PubMed |
| Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients. | Sci Rep | 2020 | 33020573 | PubTator, text mining | PubMed |
| Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell Int | 2020 | 33005100 | PubTator, text mining | PubMed |
| TRIP - T cell receptor/immunoglobulin profiler. | BMC Bioinformatics | 2020 | 32993478 | PubTator, text mining | PubMed |
| Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2020 | 32977449 | PubTator, text mining | PubMed |
| Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. | Immunity | 2020 | 32976769 | PubTator, text mining | PubMed |
| Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. | Front Oncol | 2020 | 32974152 | PubTator, text mining | PubMed |
| Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. | Cancer Med | 2020 | 32969597 | PubTator, text mining | PubMed |
| Relationship between Chromosomal Aberrations and Gene Expressions in the p53 Pathway in Chronic Lymphocytic Leukemia. | Balkan J Med Genet | 2020 | 32953405 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=55